EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Restoring cefepime activity against multidrug-resistant KPC-producing Klebsiella pneumoniae by combination with boronic acid inhibitors, MB076 and S02030

Laura J Rojas iD, Travis B Nielsen iD, Paul Pantapalangkoor, Magdalena A Taracila, Maria L Introvigne iD, Rajnikant Sharma iD, Shekhar Yeshwante iD, Maria F Mojica iD, Krisztina M Papp-Wallace iD, Andrea M Hujer, Fabio Prati iD, Emilia Caselli iD und 4 weitere

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00964-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Laura J Rojas und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Cefepime, Klebsiella pneumoniae, Anti-Bacterial Agents, beta-Lactamases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID), NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Foremost in the design of new β-lactamase inhibitors (BLIs) are the boronic acid transition state inhibitors (BATSIs). Two highly potent BATSIs being developed are S02030 and MB076 strategically designed to be active against cephalosporinases and carbapenemases, especially KPC. When combined with cefepime, S02030 and MB076 demonstrated potent antimicrobial activity against laboratory and clinical strains of Enterobacterales expressing a variety of class A and class C β-lactamases, including bla KPC-2 and bla KPC-3 . Static time-kill assays revealed the bactericidal activity of cefepime in combination with S02030 and MB076 against a multidrug-resistant KPC-producing K. pneumoniae (KPC- Kpn -1), in which a ≥ 3-log 10 decrease in the bacterial density was observed by 6 h. In vivo efficacy of MB076 in combination with cefepime was evaluated in a lung infection model where male C57BL/6 mice were infected intranasally with KPC- Kpn -1. Cefepime alone administered at 2 h post infection resulted in a 1.07 log 10 CFU reduction at 24 h, while cefepime in combination with MB076 resulted in an enhanced reduction of 2.70 log 10 CFU ( P < 0.0001) compared to the no treatment control group. In a survival analysis where mice were infected via the tail vein with KPC- Kpn -1 , all mice treated with placebo or cefepime alone (100 mg/kg) died, whereas those treated with a 1:4 molar ratio of cefepime-MB076 survived. Our data demonstrate bactericidal activity and in vivo efficacy of cefepime-MB076 comparable to ceftazidime-avibactam and support the continued development of this combination as a new treatment option for infections caused by class A carbapenemase producing Enterobacterales, particularly KPC- Kpn .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CefepimeKlebsiella pneumoniaeAnti-Bacterial Agentsbeta-LactamasesBoronic Acidsbeta-Lactamase InhibitorsKlebsiella InfectionsCephalosporinsAnimalsMicrobial Sensitivity TestsDrug Resistance, Multiple, BacterialMiceBacterial ProteinsAzabicyclo Compounds

Stichwörter der Autor:innen

BATSIKPCMB076S02030beta-lactamase inhibitorbeta-lactamasesboronic acid inhibitorcefepime

Substanzen

CefepimeAnti-Bacterial Agentsbeta-LactamasesBoronic Acidsbeta-Lactamase InhibitorsBacterial ProteinsCephalosporinsAzabicyclo Compoundscarbapenemase

Autor:innen und Institutionen

  • Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio, USA.
  • Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
  • Division of Infectious Diseases, Keck School of Medicine of the University of Southern California (USC), Los Angeles, California, USA.
  • Department of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California (USC), Los Angeles, California, USA.
  • Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

ORCID-Profile: Laura J Rojas, Travis B Nielsen, Maria L Introvigne, Rajnikant Sharma, Shekhar Yeshwante, Maria F Mojica, Krisztina M Papp-Wallace, Fabio Prati, Emilia Caselli, Philip N Rather, Gauri G Rao, Robert A Bonomo

Förderung

  • BLRD VA
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  • NIAID NIH HHS
  • U.S. Department of Veterans Affairs (VA)
  • Ministry of University and Research of Italy
  • HHS | National Institutes of Health (NIH)

Zitieren

APA

Rojas, L. J., Nielsen, T. B., Pantapalangkoor, P., Taracila, M. A., Introvigne, M. L., Sharma, R., Yeshwante, S., Mojica, M. F., Papp-Wallace, K. M., Hujer, A. M., Prati, F., Caselli, E., Spellberg, B., Rather, P. N., Rao, G. G., & Bonomo, R. A. (2025). Restoring cefepime activity against multidrug-resistant KPC-producing Klebsiella pneumoniae by combination with boronic acid inhibitors, MB076 and S02030. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00964-24

Vancouver

Rojas LJ, Nielsen TB, Pantapalangkoor P, Taracila MA, Introvigne ML, Sharma R, et al. Restoring cefepime activity against multidrug-resistant KPC-producing Klebsiella pneumoniae by combination with boronic acid inhibitors, MB076 and S02030. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00964-24

BibTeX
@article{Rojas2025,
  author = {Rojas, Laura J and Nielsen, Travis B and Pantapalangkoor, Paul and Taracila, Magdalena A and Introvigne, Maria L and Sharma, Rajnikant and Yeshwante, Shekhar and Mojica, Maria F and Papp-Wallace, Krisztina M and Hujer, Andrea M and Prati, Fabio and Caselli, Emilia and Spellberg, Brad and Rather, Philip N and Rao, Gauri G and Bonomo, Robert A},
  title = {Restoring cefepime activity against multidrug-resistant KPC-producing Klebsiella pneumoniae by combination with boronic acid inhibitors, MB076 and S02030},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00964-24}
}
Kostenlos starten →